L. Austin Doyle

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study

Anuradha Banerjee, Regina I. Jakacki, Arzu Onar‐Thomas et al. · Neuro-Oncology · 2017 · 309 citations · Full text

Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

Tanios Bekaii‐Saab, Mitch A. Phelps, Xiaobai Li et al. · Journal of Clinical Oncology · 2011 · 301 citations · Full text

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson et al. · The Lancet Oncology · 2020 · 227 citations · Full text

Medicine, Gemcitabine Versus Gemcitabine, Metronomic Therapy +6

Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

Sonali M. Smith, Koen van Besien, Theodore Karrison et al. · Journal of Clinical Oncology · 2010 · 207 citations · Full text

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Gary K. Schwartz, William D. Tap, Li-Xuan Qin et al. · The Lancet Oncology · 2013 · 186 citations · Full text